Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial

Philip J. Norris, Zhanna Kaidarova, Erica Maiorana, Silvano Milani, Mila Lebedeva, Michael P. Busch, Brian Custer, Paolo Rebulla

Research output: Contribution to journalArticlepeer-review


BACKGROUND: The current study explored whether pathogen-reduction treatment of platelet components before transfusion would decrease the risk of alloimmunization. STUDY DESIGN AND METHODS: Study participants were patients with hematologic cancer who were included in two parallel, randomized clinical trials testing pathogen-reduction treatment versus conventional platelets using the Mirasol or Intercept pathogen-reduction systems. Patients who had a baseline, pretransfusion sample and a follow-up, posttransfusion sample were included in the study (n = 179 patients in each study arm). Human leukocyte antigen antibody levels were determined using a commercial multianalyte, bead-based assay. RESULTS: The rate of human leukocyte antigen Class I alloimmunization at the clinical sites in recipients of conventional platelets was low at the highest assay cutoff (range, 1.2%-5.9%). Consistent with prior studies, human leukocyte antigen antibodies were first detected from 3 to 35 days after transfusion. There were no statistically significant differences between alloimmunization rates in patients who received pathogen-reduction treatment versus conventional platelet transfusions. Although he difference was not statistically significant, the effect size for protection from alloimmunization was greatest for high-level human leukocyte antigen Class I antibodies (approximately threefold) in the Intercept-treated patients compared with those who received conventional platelets. In the Mirasol study, only two patients and one patient in the control group developed medium-level or high-level antibodies, respectively, so it was impossible to determine an effect size for potential protection. CONCLUSIONS: The current study was not sufficiently powered to determine whether pathogen-reduction treatment provides protection from human leukocyte antigen alloimmunization in platelet transfusion recipients. The data presented will be useful in the design of future trials and endpoints powered to detect a protective effect.

Original languageEnglish
Pages (from-to)1210-1217
Number of pages8
Issue number5
Publication statusPublished - May 1 2018

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology


Dive into the research topics of 'Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial'. Together they form a unique fingerprint.

Cite this